Amicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q2 2025 Earnings of $0.01 Per Share, Zacks Research Forecasts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Investment analysts at Zacks Research issued their Q2 2025 EPS estimates for shares of Amicus Therapeutics in a report released on Wednesday, October 16th. Zacks Research analyst R. Department forecasts that the biopharmaceutical company will post earnings of $0.01 per share for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.07) per share. Zacks Research also issued estimates for Amicus Therapeutics’ Q4 2025 earnings at $0.10 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.15 EPS and FY2026 earnings at $0.46 EPS.

Several other research firms have also recently weighed in on FOLD. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of Amicus Therapeutics in a research report on Friday, September 20th. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price for the company. Morgan Stanley cut their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. JPMorgan Chase & Co. cut their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. Finally, StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Trading Up 1.8 %

Shares of FOLD opened at $10.50 on Thursday. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. The business’s 50-day moving average price is $11.15 and its 200-day moving average price is $10.55. The stock has a market cap of $3.11 billion, a PE ratio of -21.43 and a beta of 0.69. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. During the same period in the previous year, the firm earned ($0.15) EPS. The firm’s quarterly revenue was up 34.0% on a year-over-year basis.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in Amicus Therapeutics in the third quarter worth $187,000. Creative Planning increased its holdings in shares of Amicus Therapeutics by 79.6% during the third quarter. Creative Planning now owns 52,855 shares of the biopharmaceutical company’s stock valued at $564,000 after acquiring an additional 23,433 shares in the last quarter. Procyon Advisors LLC bought a new position in shares of Amicus Therapeutics during the third quarter valued at $263,000. Inspire Investing LLC increased its holdings in shares of Amicus Therapeutics by 100.5% during the third quarter. Inspire Investing LLC now owns 70,673 shares of the biopharmaceutical company’s stock valued at $755,000 after acquiring an additional 35,431 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in shares of Amicus Therapeutics by 3.8% during the third quarter. Diversified Trust Co now owns 74,501 shares of the biopharmaceutical company’s stock valued at $796,000 after acquiring an additional 2,698 shares in the last quarter.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,382,718.34. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 22,500 shares of company stock valued at $244,875 over the last quarter. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.